Bio-Rad's ddPCR Symposium India chapter is back for the 3rd year, and this time we will meet virtual.

ddPCR Symosium India
Sign up now to access to the recorded webinar.

Thank you for registering.

Please check your email for a link to the webinar. If you do not receive the confirmation within half an hour, please check your SPAM box, or send us an email at [email protected].

Be Double sure with an extra "D"

This year our annual ddPCR Symposium will go online to be both COVID-19 safe while reaching more people than ever. With three consecutive sessions over three days on three key topics , Bio-Rad will bring you nine leading experts on droplet digital PCR technology.

Learn how Droplet Digital PCR (ddPCR) is 

  • Now the gold standard for clinical liquid biopsy, having revolutionized cancer biomarker detection and quantitation. 
  • Has accelerated the development and assuring the quality of a new generation of Cell & Gene therapies.  
  • Is enabling pathologists to detect SARS-CoV-2 with more confidence with sensitive and specific multiplex assays. 

Bio-Rad will also introduce for the first time the Genesis System, addressing many of the current shortcomings of single-cell analysis including CTC isolation and enumeration. Be first in the region to meet Genesis!

Are you ready to see how ddPCR can make a difference in your research? Join the conversation.

It starts with a Droplet.
Ends in Discovery.

New to ddPCR? Learn about the technology via the Video:

Clinical Oncology

Available On-Demand

Droplet Digital PCR has become the gold standard method for Liquid Biopsy with over 1,000 publications demonstrating clinical utility across a wide range of cancer types. With the Bio-Rad QX200 system being the most widely adopted platform in Asia for routine Liquid Biopsy, the story now moves to the new field of precision monitoring. New research further expands the potential use of ddPCR technology for identifying novel biomarkers that help guide treatment decisions, and identify cancer mechanisms in new and interesting ways.

In this session, three experts in liquid biopsy will highlight key aspects of implementing ddPCR for liquid biopsy in clinic, validation of gene mutations for cancer treatment beyond EGFR and applying ddPCR for the determination of MSI status in patients with colorectal & endometrial cancer.

Speaker Name

Introduction to ddPCR in Clinical Oncology

Dr Bhaswar Maity
Senior Product Manager, Bio-Rad Laboratories, India

Dr. Bhaswar Maity, is currently working with Bio-Rad Laboratories as a senior Product Manager. He holds a MSc in Biochemistry and Phd degree in the field of Human Genetics. In his commercial career he served 15 years at various life science companies, in India & abroad. During past one & half decades, Dr. Bhaswar has worked with many Genomics & life science technologies; Sanger sequencing to Next gen Sequencing, qPCR to Digital Gene Expression, Microarray to Mass-Array Genotyping, Molecular Microbiology to Flow Cytometry at various positions; application support, Business Development, Product management & sales leadership. Trained as a Forensic DNA expert, he has transitioned his interest into human disease analysis field with various Genomics technologies.

Speaker Name

Droplet digital PCR for detection of EGFR mutations

Professor Alex Dobrovic
Head of Translational Genomics and Epigenomics Laboratory at University of Melbourne Department of Surgery, Australia

With its ability to provide absolute quantification, and its very high sensitivity and specificity, droplet digital PCR is the method of choice to study disease-associated genetic changes particularly when present at low levels or where monitoring is necessary. A series of vignettes will be provided in which the power of droplet digital PCR will be demonstrated in diagnostics and monitoring of EGFR mutations in lung cancer with an emphasis on T790M mutations.

Professor Dobrovic heads the Translational Genomics & Epigenomics Laboratory at University of Melbourne Department of Surgery. His laboratory is at the forefront of a translational research - clinical implementation interface that translates laboratory research findings into affordable diagnostics to benefit the patient population. Prof. Dobrovic has made a particular contribution to innovative methodology in cancer molecular diagnostics.

He has authored more than 200 publications in leading scientific journals

Speaker Name

A new TERT mutation analysis test on ddPCR using 7-deaza dGTP as an additive

Dr. Rekha Pai
Professor at Molecular Pathology Laboratory, Christian Medical College, Vellore- India

Since the first description of TERT promoter mutations among melanomas in 2013, TERT has been found in at least 50 other cancer types and can be the most common mutation among certain cancer types. Mutations in the TERT promoter region are restricted to two hotspots, 124 and 146 base pairs upstream of the transcription start sites, often referred to as C228T and C250T. Overtime these mutations have assumed greater importance as markers for prognostication, being associated with shorter survival and worse outcomes. However, detection of TERT promoter mutation can be challenging in tissues with low tumor cellularity, high heterogeneity and poor quality DNA, especially if they are formalin fixed. The problem is further compounded by the high GC content of the region (~80%) that can form strong secondary structures impairing strand denaturation. Validated assays often use an additive like the Q solution and locked nucleic acids (LNA) on a droplet digital PCR (ddPCR) platform, to improve the chance of amplification. Recently, 7-deaza-2’-deoxyguanosine-5’-triphosphate (7-Deaza-dGTP) has also been tested as an alternative to LNA. This presentation will highlight the utility of 7-Deaza-dGTP in TERT promoter analysis using DNA from fresh frozen and FFPE samples of glioblastoma (GBMs), with a known TERT and IDH status assessed by Sanger sequencing previously.

Summary: ddPCR is a very sensitive testing system that can be used to amplify and detect molecular changes in GC rich regions of the genome. However, an appropriate additive that helps in amplification of such complex regions might be required.

Dr. Rekha Pai, is a professor at the Department of Pathology, Christian Medical College, Vellore and supervises the day-to-day activities of the molecular pathology laboratory of the department. She trained in microbiology for a Masters’ at Vellore and then went on the complete her PhD on molecular characterization of S.pneumoniae following which she continued her work on the pneumococcus as a postdoctoral fellow at the Centers for Disease Control, Atlanta, USA. Upon her return, she took on the responsibility of developing the molecular pathology laboratory and has worked towards introducing several molecular diagnostic assays into the routine workflow. She is also a part of an active research laboratory focusing on endocrine, colorectal and brain tumors and is a part of several ongoing intra- and extramurally funded projects. She has published in several national and international journals.

Speaker Name

Microsatellite Instability Detection using a Multiplex Droplet Digital PCR System

Dr Adam S Corner
Market Development Scientist IVD, Digital Biology Group, Bio-Rad Laboratories, USA

Dr Corner holds BSc and Phd degree, obtained from the University of Leeds, Centre for Plant Biochemistry and Biotechnology. Later, he continued with several Postdoctoral positions in Leeds and Cambridge. In his commercial career he served 7 years at Applied Biosystems supporting qPCR systems, followed by 6 years at Ingenuity Systems.

Dr Corner Joined RainDance Technologies in 2011 and became part of Bio-Rad after the acquisition of RainDance in 2017.

Since 2018, he is working at Digital Biology Group as a Market Development Scientist.

Speaker Name

Panel Discussion & Q&A

Biological Therapeutics

Available On-Demand

Biologic therapeutics are complex medicines and must undergo rigorous testing to ensure consistency and safety. Bio-Rads tools for biopharmaceutical quality control range from quantitative systems for impurity testing through to high throughput methods for genome edit detection, CNV determination, and assessment of cell line genomic stability.

In this session, three experts will highlight how ddPCR technology can be used for whole cell DNA copy number analysis, AAV viral Titer quantification and introducing the all new Vericheck Mycoplasma Assay on ddPCR.

Speaker Name

Introduction to ddPCR in Therapeutic Biology

Alfred Chan
Product Manager, Asia, Bio-Rad Laboratories, APAC

Dr Alfred Chan obtained his PhD in Molecular Biology from the University of Hong Kong. He has more than 10 years of experience in molecular biology, including digital PCR and Next Gen Sequencing. Dr Chan is currently Digital Biology Product Manager at Bio-Rad APAC. Prior to this, he was a post-doc scientist in Queen Mary Hospital, Hong Kong, and has also held various positions across different Life Science companies.

Speaker Name

ddPCR Whole Cell DNA workflow effectively measures success of CAR-T cell Production

Dr Mark White
Assoc. Director, Biopharma Product Marketing at Bio-Rad Laboratories, USA

Quantifying the number of cells that contain a target piece of DNA is critical in the development of Cell Therapies and genome edited cell lines. In this seminar we will review the ddPCR Whole Cell DNA Workflow, which enables researchers to accurately count the percentage of modified cells that have their gene(s) of interest, edit(s) or knockout. With this new workflow, Bio-Rad is providing the fastest, easiest, and lowest cost way to measure cell modifications at the DNA level needed for producing high quality cell therapy products.

Mark has played a key role in the development of multiple core technology capabilities and assays alongside a multidisciplinary team of biologists and engineers at Bio-Rad and previously at Berkeley Lights Inc. Mark obtained his Ph.D. in Biomedical Sciences at the University of California, San Francisco.

Key points:

  1. Accurately measure the % of modified single cells at the DNA level
  2. Robust sensitive detection enables low cell input requirement (100–1000 cells)
Speaker Name

Vericheck ddPCR Mycoplasma Detection Solution

Dipika Gurnani
Global Product Manager, Digital Biology Group, Bio-Rad Laboratories, USA

Testing for mycoplasma contamination is a crucial QC step that requires specificity. The Bio-Rad Vericheck Droplet Digital PCR (ddPCR) mycoplasma detection kit provides the sensitivity you need via a probe-based chemistry in addition to the advantage of ddPCR inhibitor tolerance. Detect up to 112 mycoplasma species and minimize false positives to avoid disruption of your development and manufacturing processes. Utilize the positive control-based auto-thresholding, 21 CFR Part 11 compliant software for a turn-key easy data analysis.

Key points:

  1. First ever digital PCR mycoplasma test currently available for early access. 
  2. Launch date February 2021.

Dipika Gurnani is the global product manager at Bio-Rad Laboratories currently focused on biopharma products. She received her Bachelors in Engineering (major Biotechnology) from Mumbai University and completed her Masters in Bioscience from Keck Graduate Institute (KGI) in 2016.

Speaker Name

AAV Viral Titer ddPCR Solution

Paloma Shah
Global Product Manager, Digital Biology Group, Bio-Rad Laboratories, USA

Developing effective and reproducible gene therapies while ensuring safety and effectiveness in patients is complex and there is no room for error. Bio-Rad’s Droplet Digital PCR (ddPCR) assays for AAV Viral Titer utilize the accuracy, precision and sensitivity of ddPCR technology to deliver an absolute count of AAV vector genome copies in your sample. These assays work seamlessly with the Bio-Rad ddPCR product portfolio to offer the convenience of a complete workflow solution required to help you validate the quality of your therapeutic product with confidence.

Key points:

  1. New AAV Viral Titer assays: custom ddPCR Cell and Gene Therapy Assays for Gene of Interest and ready-to-order ddPCR Expert Design Assays for common vector and plasmid elements
  2. Technical content to help you transition your AAV Viral Titer assays to ddPCR

Paloma Shah is a Global Product Manager at Bio-Rad Laboratories’ Digital Biology Center, with a focus on biopharma and core ddPCR products. She has a Master of Science degree in Biotechnology Management from University of California, Irvine and a Master of Science degree in Medical Biotechnology from India’s Sardar Patel University.

Speaker Name

Panel Discussion & Q&A

Emerging Applications

Available On-Demand

Supporting Bio-Rads mission to Advance Scientific Discovery and Improve Healthcare, our efforts are driving innovation and bringing exciting new products to our users. In this session, two experts will highlight how emerging applications are making use of Digital Biology techniques to achieve better, faster data. You will also be introduced to Bio-Rads revolutionary new “Genesis System”.

Be introduced to the “Genesis System” that enables scientists to analyze molecular signatures from hundreds to millions of cells, for improved results in applications such as single-cell cytometry, single-cell transcriptomics, rare-cell (CTC) enumeration, and immune monitoring. The Genesis system provides a practical, scalable, and efficient approach to analyze rare cells.

New studies have found that Bio-Rad’s Droplet Digital PCR (ddPCR) can detect COVID-19 with greater sensitivity and precision than other molecular tests. This makes it a powerful complement to current diagnostic tools, helping clinicians and public health officials accurately identify infected individuals in a timely manner. An interesting session on ddPCR SARS Cov-2 kit -user experience.

As droplet digital PCR becomes more widely appreciated for accuracy, precision and sensitivity in routine clinical settings, the demnad grows for greater numbers of markers to be screened simultaneously. Learn the basics of multiplex assay development & optimization, why multiplex ddPCR succeeds where qPCR usually fails and explore the full potential of ddPCR.

Speaker Name

Evolution with innovation - defining the future of digital Biology

Bhaswar Maity
Senior Product Manager, Bio-Rad Laboratories, India

Dr. Bhaswar Maity, is currently working with Bio-Rad Laboratories as a senior Product Manager. He holds a MSc in Biochemistry and Phd degree in the field of Human Genetics. In his commercial career he served 15 years at various life science companies, in India & abroad. During past one & half decades, Dr. Bhaswar has worked with many Genomics & life science technologies; Sanger sequencing to Next gen Sequencing, qPCR to Digital Gene Expression, Microarray to Mass-Array Genotyping, Molecular Microbiology to Flow Cytometry at various positions; application support, Business Development, Product management & sales leadership. Trained as a Forensic DNA expert, he has transitioned his interest into human disease analysis field with various Genomics technologies.

Speaker Name

Using Celselect Technology for Analysis of Rare Cells and Liquid Biopsies

Dr. Brandan Walters
Field Application Scientist at Celsee, Inc.

For the last decade, Celsee has been a pioneer in developing single cells applications now used all over the world. Bio-Rad’s acquisition of Celsee in April 2020 has been received with excitement and opened new opportunities. One of these new efforts has been the expansion of Celselect applications to new markets with improved performance. Celselect technology is used on the Genesis system to process circulating tumor cell (CTC) enrichment and enumeration. It has been designed for use in academic, clinical, and pharmaceutical labs that seek to study rare populations of cells within complex heterogeneous liquid samples. It can facilitate retrieval of isolated cells to be used in additional methods of analysis for proteomic and genomic expression or perform immunohistochemical staining. The system is designed around an open platform for user developed assays, markers, and automated microscopy and counting algorithms. During this talk will discuss the importance of CTCs, the various workflows for different Celselect applications on the Genesis instrument, important data sets, and potential synergies with other Bio-Rad assays.

Key points:

  1. Celsee is a Bio-Rad company producing innovative technologies to compliment and grow existing Bio-Rad technologies
  2. Celselect technologies contribute multiple assays for CTC research including rare cell enumeration and enrichment

Brandan earned a BA in applied physics from Albion College, a BSE in biomedical engineering from Columbia University, and an MSE and PhD from the University of Michigan, both in biomedical engineering. He started his industrial career as a Field Application Scientist with Celsee in 2018. His first two years with the company were spent supporting collaborations and assisting early customers with assay development. When he wasn’t in the field, Brandan spent time in the lab contributing his field experience toward improved product development. In 2020, Brandan transitioned to his current role of Product Manager after the acquisition of Celsee by Bio-Rad. He now uses his experience in the lab and with customers to advance Celsee’s Celselect technologies and has started working with Bio-Rad’s SureCell ATAC-Seq product.

Speaker Name

Quantitative Multiplexing Digital PCR - Easier than is seems

Francisco Bizouarn
Market Development Team Manager - Digital Biology Group, Bio-Rad Laboratories, USA

Accurate quantification of multiplexed targets in a single tube can be challenging due to reaction mix monopolization by the higher abundance targets. Partitioning these reactions into thousands of sub-reactions and subsequently analyzing each for the presence of the target of interest removes this bias and allows for the accurate count of individual targets within a single reaction. This talk will present examples of advanced multiplexing (3 to 5 plex using 2 colors and 8plex using 4 colors) and describe assay setup and optimization strategies.

Francisco Bizouarn joined Bio-Rad in 2000 to support quantitative PCR (qPCR) technology as a Field Applications Specialist (FAS) in the southeast United States. In 2006, he moved into the role of International FAS for our global Gene Expression Division to promote best practices in qPCR around the world. In 2011, he began working on droplet digital PCR applications (ddPCR) and joined the Digital Biology group. Currently, his focus is supporting and promoting best practices in quantitation, detection, and sample discrimination applications that take advantage of the high resolution and sensitivity provided by the power of Droplet partitioning.

Speaker Name

Panel Discussion & Q&A

Register Now!